NDAORALTABLET, EXTENDED RELEASE
Approved
Dec 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 15h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LEXXEL is a fixed-dose combination oral tablet containing enalapril maleate (ACE inhibitor) and felodipine (calcium channel blocker) in extended-release formulation. It is indicated for hypertension management in patients requiring dual-agent therapy. The combination works synergistically to reduce blood pressure through ACE inhibition and vasodilation.
LOE Approaching
With LOE approaching and moderate competitive pressure (30%), the brand team is likely focused on lifecycle management and transitioning to generic strategies rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LEXXEL offers experience in lifecycle management, generic transition planning, and commercial optimization in a mature product environment. Roles are primarily commercial-focused with emphasis on payer strategy and market access rather than growth-oriented activities.
Brand ManagerField Sales Representative
Worked on LEXXEL at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.